15289-s-bos

96 | Chapter 6 References 1. Rosvall M, Janzon L, Berglund G et al. Incident coronary events and case fatality in relation to common carotid intima-media thickness. J Intern Med 2005; 257:430-437. 2. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232:34-47. 3. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003; 111:1795-1803 4. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007; 4:214-225. 5. Umans-Eckenhausen MA, Sijbrands EJ, Kastelein JJ, Defesche JC. Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation 2002; 106:3031-3036. 6. Sivapalaratnam S, van Loendersloot LL, Hutten BA et al. Long-term LDL-c lowering in heterozygous familial hypercholesterolemia normalizes carotid intima-media thickness. Atherosclerosis 2010; 212:571-574. 7. VuorioA, Docherty KF, Humphries SE etal. Statin treatment of childrenwith familial hypercholesterolemia- -trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? Atherosclerosis 2013; 226:315-320. 8. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012; 97:3956-3964. 9. Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med 2013; 273:6-30 10. Jansen AC, van Aalst-Cohen ES, Tanck MW et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004; 256:482-490. 11. Seed M, Hoppichler F, Reaveley D et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990; 322:1494-1499. 12. Bos S, Yayha R, van Lennep JE. Latest developments in the treatment of lipoprotein (a). Curr Opin Lipidol 2014; 25:452-460. 13. Belcaro G, Nicolaides AN, Ramaswami G et al. Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: a 10-year follow-up study (the CAFES-CAVE study(1)). Atherosclerosis 2001; 156:379-387. 14. Bots ML, Hoes AW, Koudstaal PJ et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96:1432-1437. 15. Burke GL, Evans GW, Riley WA et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 1995; 26:386-391. 16. Polak JF, Szklo M, Kronmal RA et al. The value of carotid artery plaque and intima-media thickness for incident cardiovascular disease: the multi-ethnic study of atherosclerosis. J Am Heart Assoc 2013; 2:e000087. 17. Schreiner PJ, Morrisett JD, Sharrett AR et al. Lipoprotein[a] as a risk factor for preclinical atherosclerosis. Arterioscler Thromb 1993; 13:826-833. 18. Baldassarre D, Tremoli E, Franceschini G et al. Plasma lipoprotein(a) is an independent factor associated with carotid wall thickening in severely but not moderately hypercholesterolemic patients. Stroke 1996; 27:1044-1049. 19. Nordestgaard BG, Chapman MJ, Humphries SE et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34:3478-3490a. 20. Vanoli D, Lindqvist P, Wiklund U et al. Fully automated on-screen carotid intima-media thickness measurement: a screening tool for subclinical atherosclerosis. J Clin Ultrasound 2013; 41:333-339. 21. Kostner GM, Avogaro P, Cazzolato G et al. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 1981; 38:51-61.